1. |
From the Editor |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 2-2
&NA;,
Preview
|
PDF (792KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
2. |
Facing the challenges of IBD therapy |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 3-4
Theresa Szeto,
Preview
|
PDF (1540KB)
|
|
摘要:
Despite the absence of an identified causative factor in inflammatory bowel disease (IBD), improvements in therapy are being made. New agents, such as anti-tumour necrosis factor monoclonal antibody, are showing impressive results in early trials of patients with Crohn's disease. And older agents, such as mesalazine, are being studied in various combinations and regimens to identify optimal use. These were among the numerous issues relating to IBD that were discussed at the Annual Meeting of the American Gastroenterological Association and Digestive Disease Week [New Orleans, US; May 1994].
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 5-5
&NA;,
Preview
|
PDF (736KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
4. |
Paediatric perspectives |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 6-6
&NA;,
Preview
|
PDF (790KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
5. |
Hepatitis B vaccination without screening justified? |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 7-7
&NA;,
Preview
|
PDF (696KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
6. |
Physicians underestimate drug costs |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 8-8
&NA;,
Preview
|
PDF (712KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
7. |
Buying time with batimastatnew hope for cancer patients |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 9-9
Ian Mundell,
Preview
|
PDF (823KB)
|
|
摘要:
Batimastat represents a curious departure in anticancer therapy since it does not kill the cancer cells, but rather impedes their progress. Accordingly, it may have promise as a management tool that will buy time for other interventions. Phase I/II trials of the drug have shown that it is safe, and have also indicated efficacy in controlling cancer progression. Now, British Biotechnology and its collaborators are setting out to repeat the results on a larger scale. They also hope to elucidate the drug's mechanism.
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 10-10
&NA;,
Preview
|
PDF (748KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 11-11
&NA;,
Preview
|
PDF (763KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 940,
1994,
Page 12-12
&NA;,
Preview
|
PDF (734KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|